David Kaplan

23PUBLICATIONS

183CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Legal institutions (incl. courts and justice systems)HaematologyCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (23)

Sort by Publication Date:

|Jun 10, 2026

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

|Apr 27, 2026

Outcomes of Simultaneous Liver-Kidney Transplant and Kidney After Liver Transplant Using the Safety Net Criteria-A Single-center Experience.

|Apr 14, 2026

Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration.

Shalini Bansal, Priya Amin, Courtney Williamson

|Sep 26, 2025

Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.

Marijana Vujkovic, David E Kaplan, Jonas Ghouse

|Oct 26, 2024

Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.

David E Kaplan, Ruoding Tan, Cheryl Xiang

|Sep 23, 2024

Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.

Peiman Habibollahi, Alexey Gurevich, James Z Hui

Pageof 4

Frequent Collaborators

Marijana Vujkovic

Benjamin F Voight

Julie Lynch

Philip Tsao

Marina Serper

Silvia Vilarinho

Kyong-Mi Chang

Gregory Nadolski

Terence P Gade

Themistocles L Assimes

Frequent Collaborators

Marijana Vujkovic

Benjamin F Voight

Julie Lynch

Philip Tsao